News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
23 December 2025

On Your Radar for 2026: The Must-Watch Trends From 2025

Explore three of the top export and commodity finance trends going into 2026, with news, in-depth articles, deals data, and event content curated by Exile Flow AI. Green...

Perspective
09 January 2026

Vulcan lithium: DFIs and ECAs combine for critical minerals

The EIB is anchoring another major DFI-ECA package for a major European energy transition project. Can it succeed where earlier complex mega-projects have struggled?